January 18, 2022: Novaliq GmbH

Dermaliq Therapeutics Signs USD 15 Million Series A Round to Advance Three Transformative Drug Therapies into Clinical Trials

Dermaliq Therapeutics, Inc. is an independent private pharmaceutical company emerged from Novaliq
Spin-off to unlock value in the space of medical dermatology by using Novaliq’s transformative technology outside eye care
3E Bioventures Capital and Beijing Whale Technology Corporation Ltd join as new investors
Proceeds will be used for three Phase 1/2a clinical development programs in dermatology

Novaliq GmbH, 3E Bioventures Capital and Beijing Whale Technology Corporation Ltd. today announced the establishment of Dermaliq Therapeutics, Inc (Dermaliq), a newly formed Delaware-based pharmaceutical development company, and the signing of a USD 15 million Series A financing round. 3E Bioventures Capital, a leading international life science investor, led the round and was joined by Beijing Whale Technology Corporation Ltd. Dermaliq´s existing shareholder Novaliq has transferred, and licensed Intellectual Property (IP) related to the field of dermatology to Dermaliq.

Please read the whole article here

News 2022, Novaliq GmbH

January 17, 2022: CureVac AG

CureVac Chief Technology Officer to Pursue New Career outside Biotech Industry

CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced that the company’s Chief Technology Officer, Dr. Mariola Fotin-Mleczek, will resign from CureVac effective January 31, Mariola exits her role at CureVac after nearly 16 years of scientific leadership at the company, and 33 years in Germany, with plans to pursue a family business outside the biotech industry in her home country of Poland. Further development of CureVac’s unique mRNA technology platform will be led by Dr. Igor Splawski, Chief Scientific Officer of CureVac, and spearheaded by Dr. Patrick Baumhof, Senior Vice President Technology, who has a 15-year scientific tenure with the company. The consolidated scientific frontend will seamlessly integrate with the subsequent clinical development of new mRNA-based vaccines and therapeutics.

Please read the whole article here

CureVac AG, News 2022

December 30, 2021: Cosmo Pharmaceuticals NV

Cosmo Pharmaceuticals Announces Hiring of Head of Investor Relations and Senior Leadership Change

Cosmo Pharmaceuticals N.V. (“Cosmo”) today announced that Ms. Hazel Winchester has been appointed to the position of Head of Investor Relations and will take up the position on the 10th of January, 2022.

Please read the whole article here

Cosmo Pharmaceuticals NV, News 2021

December 21, 2021: Novaliq GmbH

NOVALIQ ANNOUNCES POSITIVE TOPLINE RESULTS FOR SECOND PHASE 3 TRIAL (ESSENCE-2) OF CYCLASOL® IN DRY EYE DISEASE

Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, today announced key results of the second pivotal Phase 3 trial (ESSENCE-2) evaluating the investigational drug CyclASol® for the treatment of dry eye disease (DED).

Please read the whole article here

News 2021, Novaliq GmbH

December 17, 2021: Cosmo Pharmaceuticals NV

COSMO PHARMACEUTICALS N.V. AND CASSIOPEA S.P.A ANNOUNCE SETTLEMENT OF PUBLIC EXCHANGE OFFER FOR ALL PUBLICLY HELD SHARES IN CASSIOPEA S.P.A.

Cosmo Pharmaceuticals N.V. (“Cosmo”) and Cassiopea S.p.A. (“Cassiopea”) announce the settlement of the public exchange offer by Cosmo in accordance with articles 125 et seq. of the Federal Act on Financial Markets Infrastructure and Market Conduct in Securities and Derivatives Trading of 19 June 2015 for all publicly held registered shares in Cassiopea (“Offer”).

Please read the whole article here

Cosmo Pharmaceuticals NV, News 2021

December 16, 2021: Novaliq GmbH

PHASE 3 TRIAL OF SHR8058 EYE DROPS (PERFLUOROHEXYLOCTANE) CONDUCTED BY JIANGSU HENGRUI PHARMACEUTICALS IN THE PEOPLE’S REPUBLIC OF CHINA SHOWS STATISTICALLY SIGNIFICANT TOPLINE RESULTS

Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, today provided a development update on the phase 3 trial of SHR8058 eye drops (perfluorohexyloctane) for the treatment of dry eye disease (DED) associated with Meibomian gland dysfunction (MGD) conducted by Jiangsu Hengrui Pharmaceuticals Co., Ltd. (“Hengrui Pharma”) (SSE:600276) in the People’s Republic of China showing statistically significant topline results compared to 0.6% sodium chloride solution.[1]

Please read the whole article here

News 2021, Novaliq GmbH

December 15, 2021: AC Immune SA

AC Immune Awarded Two Michael J. Fox Foundation Grants to Advance Small Molecule Parkinson’s Disease Programs

Funding to accelerate the development of first-in-class brain penetrant small molecules to inhibit a-syn aggregation and NLRP3 inflammasome activation in Parkinson’s disease (PD)

Programs targeting intracellular disease mechanisms complement AC Immune’s extensive PD portfolio and strengthen AC Immune’s Precision Medicine approach for PD

Additional validation of AC Immune’s Morphomer® small molecule platform

AC Immune SA, a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced it has been awarded two grants, a total of approximately USD 1.5 million, from The Michael J. Fox Foundation for Parkinson’s Research (MJFF), to develop first-in-class brain penetrant small molecules targeting alpha-synuclein (a-syn) and the (NOD)-like receptor protein 3 (NLRP3) inflammasome pathway in Parkinson’s disease (PD). These grants further expand AC Immune’s research efforts with MJFF following previous grants awarded since 2015 to support the development of a-syn-targeted brain imaging molecules.

Please read the whole article here

AC Immune SA, News 2021

December 14, 2021: Immatics Biotechnologies GmbH

Bristol Myers Squibb secures global exclusive license to Immatics’ TCR bispecific program IMA401; companies will collaborate on development with Immatics retaining a co-promotion option in the US
Immatics to receive upfront payment of $150 million and additional milestone payments of up to $770 million plus tiered double-digit royalties on net product sales

Immatics N.V. (“Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, and Bristol Myers Squibb (NYSE: BMY), today announced that they have entered into a license, development and commercialization agreement (the “agreement”) for Immatics’ TCR Bispecific candidate, IMA401.

Please read the whole article here

Immatics Biotechnologies GmbH, News 2021

December 9, 2021: Apogenix AG

Apogenix Receives €20.7 Million in Public Funding for Pivotal Study and Preparation for Market Production of Asunercept for the Treatment of COVID-19

Main investor dievini supports project with additional €5.1 million
Apogenix is one of six therapeutics developers in Germany selected to receive funding totaling €150 million

Apogenix, a biopharmaceutical company developing next generation immunotherapeutics, announced today that it has received a funding commitment from the German Federal Ministries of Health (BMG) and Education and Research (BMBF) in the amount of €20.7 million as part of the funding initiative “Clinical development of COVID-19 drugs and their manufacturing capabilities.” At the beginning of September, the two ministries held a press conference to announce the companies that had been selected for funding. Apogenix has just received the official funding notice. The funds will be used to finance a phase III clinical trial (ASUCOV) with CD95 ligand inhibitor asunercept in moderately to severely ill, hospitalized COVID-19 patients. In addition, the GMP production process for asunercept will be further developed to market maturity and the required material for the phase III clinical trial will be produced. The German government will fund 80 percent of these costs, and the remaining 20 percent will be covered by Apogenix’s main investor dievini Hopp BioTech Holding GmbH & Co. KG.

Please read the whole article here

Apogenix AG, News 2021

December 7, 2021: Cosmo Pharmaceuticals NV

COSMO PHARMACEUTICALS N.V. AND CASSIOPEA S.P.A. PUBLISH DEFINITIVE FINAL RESULTS OF PUBLIC EXCHANGE OFFER FOR ALL PUBLICLY HELD SHARES OF CASSIOPEA S.P.A.

Cosmo Pharmaceuticals N.V. (“Cosmo”) and Cassiopea S.p.A. (“Cassiopea”) today announced the definitive final results for the public exchange offer by Cosmo in accordance with articles 125 et seq. of the Federal Act on Financial Markets Infrastructure and Market Conduct in Securities and Derivatives Trading of 19 June 2015 for all publicly held registered shares in Cassiopea (“Offer”).

Please read the whole article here

Cosmo Pharmaceuticals NV, News 2021